Expanding its reach in dermatology, Eli Lilly has agreed to acquire skin specialist Dermira for a purchase price of US$1.1 B. With the deal, Lilly adds a late-stage atopic dermatitis candidate, lebrikizumab, to its portfolio, as well as Qbrexza® (glycopyrronium) cloth, a marketed treatment for primary axillary hyperhidrosis. The deal comes as Lilly’s blockbuster osteoporosis drug Forteo® (teriparatide) is expected to face near-term generic competition.